Introduction
A synthetic and potent estrogen receptor agonist, 17α-ethinylestradiol (EE2) is a major estrogen component of oral contraceptive formulations (Zhang et al., 2007) . Although EE2 is well absorbed, oral bioavailability is variable (e.g., 20 to 65%) because of extensive first-pass metabolism in both the intestine and liver. Such metabolism involves sulfotransferase-catalyzed 3-O-sulfation, UDP-glucuronosyltransferase-catalyzed 3-O-glucuronidation, and cytochrome P450-mediated 2-hydroxylation. Of the three pathways, sulfation dominates and the resulting metabolite (EE2-Sul) circulates at concentrations that are at least one order of magnitude greater than parent EE2 (Back et al., 1980) . The results of various pharmacokinetic and radiolabeled studies have demonstrated that EE2 undergoes enterohepatic recirculation, with the various metabolites recovered in bile (~40% of dose) and urine (~30 of the dose) (Maggs et al., 1983) .
The presence of both EE2-Sul and EE2-Glu in the urine is thought to reflect active transport in kidneys (Maggs et al., 1983) .
In an accompanying manuscript (Han et al., 2010) , EE2-Sul was shown to be a substrate of numerous liver-expressed transporters (OATP1B1, OATP2B1, NTCP and BCRP). However, information related to the transporters involved in the renal excretion of EE2-Sul is lacking. In the human kidney, a variety of SLC and ABC transporters are expressed in proximal tubule cells and play a major role in the uptake and secretion of organic compounds (Lee and Kim, 2004; Robertson and Rankin, 2006) . Namely, OAT1 and OAT3 are SLCs expressed on the basolateral membrane, whereas OAT4, MRP2, MRP4, and BCRP are apical transporters known to actively transport organic anions. However, additional transporters such as OCT2 (e.g., prostaglandins) and MATE1 (e.g., estrone-3-sulfate, acyclovir, and ganciclovir) are also able to transport organic This article has not been copyedited and formatted. The final version may differ from this version. anions (Tanihara et al., 2007) . Therefore, the purpose of the present study was to characterize the drug transporters that are responsible for renal excretion of EE2-Sul. Studies were performed with HEK-293 cells containing stably-expressed OCT2, OAT3, OAT4 and MATE1, MDCK cells expressing OAT1, and insect cell (Sf9) membrane vesicles expressing MRP4. It is concluded that circulating EE2-Sul is taken up by OAT3 and effluxed by OAT4 at the brushborder membrane of human renal proximal tubule cells. The latter may function coordinately with BCRP, because EE2-Sul is also a BCRP substrate (Han et al., 2010) . Therefore, at least three transporters may play a role in the renal elimination of EE2-Sul.
This article has not been copyedited and formatted. The final version may differ from this version. (Li et al., 1999; Schrag et al., 2004) . The latter (250 μCi) was transferred in ethanol into a test tube with a screw cap. The sample was gently evaporated under a stream of nitrogen to near dryness. A stir bar was added to the test-tube followed by addition of 0.4 mg PAPS (in 0.2 mL of 0.1 M phosphate buffer, pH 7.0), 100 μL (2 mg) pooled human liver cytosol (BD Biosciences), and 0.7 mL of 0.1 M phosphate buffer (pH 7.0). The reaction was started at 37 °C and its progress was monitored by radio-HPLC. A second batch of PAPS (2 mg in 0.5 mL of 0.1 M phosphate buffer, This article has not been copyedited and formatted. The final version may differ from this version. and MATE1) and estrone-3-sulfate (1 μM, OAT3 and OAT4) were used as substrates for the different transporters. Additionally, the inhibitors of each transporter were selected as follows;
This article has not been copyedited and formatted. The final version may differ from this version. Total cellular protein was measured using the BCA protein assay kit supplied by Pierce (Rockford. IL).
Transport Studies with MRP4-expressing Membrane Vesicles
The transport studies were performed using a rapid filtration technique according to the manufacturer's protocol with a minor modification (Genomembrane, Inc., Yokohama, Japan). In brief, 30 µL of transport medium (50 mM MOPS-Tris (pH 7.0), 70 mM KCl, 7.5 mM MgCl 2 , and 2 mM glutathione), containing membrane vesicles (50 µg of protein) and test compounds, 
Estimation of Kinetic Parameters
To estimate kinetic parameters for saturable transport, the uptake rate (V) was fitted to the following equations by means of nonlinear least-squares regression analysis using WinNonlin (Scientific Consulting Inc., Cary, NC).
The kinetic parameters describing the uptake of EE2-Sul were obtained by using the following equation:
In the case of a single saturable component (OAT3),
and for a system consisting of two saturable components (OAT4),
where V and C are the uptake rate and concentration of substrate, respectively, and K m and V max represent the half saturation concentration (Michaelis constant), the maximum transport rate, respectively.
This article has not been copyedited and formatted. The final version may differ from this version. OAT3 and OAT4 uptake activity in HEK-293 cells was determined after subtracting the uptake by mock-transfected cells from total uptake by the OAT3-or OAT4-expressing cells.
All data are expressed as the mean ± SD, and statistical analysis was performed by a 2-way ANOVA followed by a post-hoc Dunnett's test. The criterion of significance was taken to be P <0.05 or 0.01.
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Results
Uptake of EE2-Sul into OCT2-Expressing HEK-293 Cells.
Prior to conducting transport studies, stably transfected OCT2-expressing HEK-293 cells were subjected to real time PCR analysis and the results revealed significant over-expression (~400,000-fold) of OCT2 (vs mock cells) (data not shown). Furthermore, differential uptake of MPP into OCT2/HEK-293 cells (versus mock/HEK-293 cells) was evident (Table 1 ). The uptake of MPP was also inhibited (>90%) by imipramine (200 µM), a known OCT inhibitor (Urakami et al., 2001) . In contrast to MPP, differential uptake of EE2-Sul into OCT2/HEK-293 cells was not observed and imipramine had no effect. Under the conditions of the study, therefore, EE2-Sul did not behave as an OCT2 substrate (Table 1) .
Uptake of EE2-Sul into OAT1, OAT3, and OAT4-Expressing Cells.
As shown previously (Aslamkhan et al., 2003) , it was evident that PAH uptake into OAT1/MDCK cells was significantly higher (15.9 vs 0.77 pmol/min3 min -1 ) than mock/MDCK cells ( Table 1) . The OAT1-mediated uptake was inhibited by an OAT1 inhibitor (BSP, 50 µM), suggesting OAT1/MDCK cells were functionally active. In parallel, when EE2-Sul uptake was measured, there was no evidence for differential uptake into OAT1/MDCK cells (Table 1) .
Therefore, as with OCT2, EE2-Sul did not serve as a substrate of OAT1.
This article has not been copyedited and formatted. The final version may differ from this version. and the over-expression of OAT3 in the former (243,000-fold) was confirmed (data not shown).
The high expression of OAT3 was reflected in the differential uptake of estrone-3-sulfate, which was inhibited (>90%) by BSP ( Figure 1A ). When the uptake by mock and OAT3/HEK-293 cells was compared, significantly high uptake of EE2-Sul was apparent with OAT3/HEK-293 cells ( Figure 1B ). The uptake was reduced with OAT3 inhibitors (BSP, cimetidine, probenecid) in a concentration-dependent manner, but no change was observed with TEA (non-inhibitor) ( Figure   1C ). These results suggest EE2-Sul is an OAT3 substrate. As shown in Figure 2A , EE2-Sul (10 nM to 200 µM) uptake increased nonlinearly with increasing concentration. The kinetics of transport was analyzed using the Eadie-Hofstee equations to derive estimates of the kinetic parameters required for the nonlinear regression analysis and to assess the number of transport systems involved. As shown in Figure 2B , the Eadie-Hofstee plot (V versus V/C) of EE2-Sul transport presented one linear component, which was described by single-K m kinetics (K m = 21.1 ± 2.7 µM; V max 67.5 ± 3.5 pmol/mg/min).
As with OAT3, real time PCR results showed high expression of OAT4 mRNA in OAT4/HEK-293 cell (217,000-fold) (data not shown), and differential (BSP-inhibited) uptake of estrone-3-sulfate and EE2-Sul was observed also ( Figure 3A ). EE2-Sul showed preferential uptake into OAT4/HEK-293 cells over mock/HEK-293 cells ( Figure 3B ). The uptake by OAT4/HEK-293 cells was decreased in the presence of OAT4 inhibitors, BSP, methotrexate, and probenecid, but not TEA (non-inhibitor) ( Figure 3C ). OAT4-mediated uptake was saturable, as EE2-Sul concentration increased ( Figure 4A ). To confirm the type of EE2-Sul transport, the OAT4-dependent uptake of EE2-Sul (10 nM to 200 µM) into HEK-293 cells was analyzed using the This article has not been copyedited and formatted. The final version may differ from this version. Eadie-Hofstee plot and shown in Figure 4B . Unlike OAT3, the plot characterized two obviously different transport systems: a high-affinity, low-velocity system (K m1 = 1.6 ± 1.8 µM, V max1 = 27.5 ± 21.42 pmol/min/mg) and a low-affinity, high-velocity system (K m2 = 195 ± 138 µM, and V max2 = 599 ± 225 pmol/min/mg). Therefore, EE2-Sul behaved as an OAT3 and OAT4 substrate. uptake of EE2-Sul into MATE1/HEK-293 cells was not observed and pyrimethamine had no effect (Table 1) . Under the conditions of the study, therefore, EE2-Sul did not behave as a MATE1 substrate.
Uptake of EE2-

Uptake of EE2-Sul by MRP4-Expressing Membrane Vesicles.
The potential for active transport of EE2-Sul was evaluated with insect cell (Sf9) membrane vesicles expressing MRP4. In this instance, the vesicles were shown to be functionally Figure 5A ). Under the same assay conditions, however, no ATP-dependent uptake of EE2-Sul was observed ( Figure 5B ).
Discussion
Following the oral administration of EE2, EE2-Sul circulates in the blood at high concentrations (6-to 23-fold greater than EE2) (Back et al., 1980) . In addition, a significant amount of the EE2 dose is recovered in urine as EE2-Sul (Maggs et al., 1983) . Although EE2 passive permeability is high (Zhang et al., 2007) , due to its physicochemical properties, it is likely that EE2-Sul would require transporter-mediated uptake and efflux during the course of its elimination. Therefore, an attempt was made to evaluate the transporters that might be involved in its renal elimination.
Because the localization of different renal transporters is known (Lee and Kim, 2004; Robertson and Rankin, 2006) , it was possible to conduct EE2-Sul phenotyping studies with a panel of uptake transporters (e.g., OCT2, OAT1 and OAT3) known to be expressed on the basolateral membrane and efflux transporters (e.g., OAT4, MATE1 and MRP4) expressed on the brush border membrane of proximal tubule cells. Collectively, the data indicated that EE2-Sul behaves as an OAT3 and OAT4 substrate. Unfortunately, at the time of study it was not possible to evaluate EE2-Sul as a substrate of additional renal transporters such as OATP4C1 (Mikkaichi et al., 2004) .
Although various OCT family members are recognized as cation transporters, OCT1 and OCT2
have been shown to flux anionic compounds such as prostaglandin E2 and prostaglandin F2α (Kimura et al., 2002) . However, prostaglandin differs structurally from EE2-Sul and the latter did not serve as an OCT2 substrate (Table 1) .
This article has not been copyedited and formatted. The final version may differ from this version. . On the other hand, significant uptake of EE2-Sul was observed with OAT3 over-expressing HEK-293 cells (Figure 1) . A similar finding has been reported for other sulfate conjugates such as estrone-3-sulfate (Cha et al., 2001; Tahara et al., 2005) , DHEAS (Cha et al., 2001) , and indoxyl sulfate (Deguchi et al., 2004) . The K m value of EE2-Sul obtained in our experiments (21 µM) was slightly higher than that of estrone-3-sulfate (9.5 µM) (Tahara et al., 2005) and DHEAS (13 µM) (Nozaki et al., 2007) . However, OAT1 uptake of EE2-Sul in OAT1-transfected cells was similar to that of vector-transfected cells ( Table 1 ), suggesting that EE2-Sul is not an OAT1
substrate. The differentiation between OAT3 and OAT1 is similar to that reported for estrone-3-sulfate (Sweet et al., 2002) and DHEAS (Nozaki et al., 2007) . Interestingly, indoxyl sulfate serves as an OAT1 and OAT3 substrate (Deguchi et al., 2004) .
Anionic drug transport in the kidney is more often than not OAT3-mediated, because the transporter is one of the major renal SLCs (Lee and Kim, 2004) . The results of the present study, therefore, implicate OAT3 as a major player in the active (renal) uptake of circulating EE2-Sul.
Because EE2-Sul was also found to be a substrate of OAT4, expressed on the brush border (apical) membrane of renal proximal tubules (Babu et al., 2002) , it is assumed that OAT3 and OAT4 function in a coordinated manner to govern the overall renal-dependent elimination of the conjugate (Maggs et al., 1983) . It is noteworthy that OAT4-mediated uptake into HEK-293 cells was described by a two-K m model (K m1 = 1.6 ± 1.8 µM; K m2 = 195 ± 138 µM) (Figure 4 (Kimura et al., 2002) . However, the overall transporter phenotype of estrone-3-sulfate (Cha et al., 2001; Tamai et al., 2001; Lee and Kim, 2004) resembles that of EE2-Sul (Han et al., 2010, this study), because OATP1B1-, OATP2B1-and OAT3-mediated uptake is evident also. Furthermore, OAT4 is known to be an apical organic anion/dicarboxylate exchanger and functions as an apical pathway for the reabsorption of some organic anions in renal proximal tubules driven by an outwardly directed dicarboxylate gradient (Ekaratanawong et al., 2004) . Consequently, OAT4-mediated secretion or reabsorption for EE2-Sul into the proximal tubule is possible.
Aside from OAT4 on the brush border membrane, other transporters on the brush border membrane of renal proximal tubule cells can be considered as EE2-Sul transporters. For example, MATE1 and MATE2-K are known to recognize some anionic compounds (e.g., acyclovir, ganciclovir and estrone-3-sulfate), even though cationic drugs are favored as substrates (Tanihara et al., 2007; Terada and Inui, 2008) . The results of the present study showed that EE2-Sul is not a MATE1 substrate ( Table 1 ). Given that the specificity of MATE1 and MATE2-K is similar (Terada and Inui, 2008) , it is unlikely that MATE2-K plays a role in the urinary excretion of EE2-Sul.
MRP4 has also been reported to be responsible for the renal secretion of some organic anions such as estradiol-17β-D-glucuronide (van Aubel et al., 2002) , DHEAS (Zelcer et al., 2003) , folic acid (Chen et al., 2002) and uric acid (Van Aubel et al., 2005) . In our hands, however, no ATPThis article has not been copyedited and formatted. The final version may differ from this version. (Table 2) . At the same time, formation of EE2-Sul is mediated by sulfotransferases in both the intestine and liver, while conversion back to EE2 is catalyzed by sulfatases in each tissue (Zhang et al., 2007) . Therefore, formation, distribution and elimination of EE2-Sul is dependent on numerous enzymes and transporters ( Figure 6 ).
This article has not been copyedited and formatted. The final version may differ from this version. Although not the focus of the present study, EE2-Glu is also significantly excreted in the urine (Maggs et al., 1983) . However, the transporters involved in EE2-Glu renal elimination have not been studied systematically. The uptake of EE2-Glu into the proximal tubule cells may occur via OAT3, as is the case with EE2-Sul, because OAT3 is able to transport glucuronide conjugates (Cha et al., 2001) . Since OAT4 interacts preferentially with sulfate conjugates rather than glucuronide conjugates (Cha et al., 2000) , the transport pathway of EE2-Glu may be different from that of EE2-Sul on the brush border membrane of proximal tubule cells and the involvement of MRP2 is inferred (Chu et al., 2004) . Additionally, other efflux transporters such as BCRP and MRP4 may also interact with EE2-Glu, as in the case of estradiol-17β-Dglucuronide (Chen et al., 2003) , SN-38-glucuronide (Nakatomi et al., 2001 ) and methylumbelliferone glucuronide (Suzuki et al., 2003) .
EE2 has been in use for many years and the original work of Maggs et al (1983) described the recovery of various EE2 metabolites in the urine and bile of female subjects receiving a radiolabel dose. At the time, the active secretion of EE2-Glu and EE2-Sul was suspected. With time, it has been possible to obtain additional information and emerging data now point to the coordinated role of various drug-metabolizing enzymes and transporters that govern the metabolism and pharmacokinetics of EE2 itself, as well as the distribution and elimination of its major (conjugated) metabolites (Zhang et al., 2007; Han et al., 2010) . Any one of the enzymes involved in EE2 metabolism, or transporters involved in EE2-Glu or EE2-Sul transport, could be subject to inhibition (or induction) by perpetrator drugs, or impacted by polymorphisms (Zhou and You, 2007; Cusatis and Sparreboom, 2008; Maeda and Sugiyama, 2008) . Such information Once in the gut lumen, EE2 is absorbed (passively) and can undergo metabolism (e.g., sulfation to EE2-Sul) in enterocytes. BCRP can transport EE2-Sul back into the gut lumen. A considerable This article has not been copyedited and formatted. The final version may differ from this version. 
